Special Reports
FiercePharma's most popular stories of 2008
Welcome to FiercePharma's look back at our most popular stories and features of 2008. While a number of topics are represented in our top 10 stories, layoffs seem to be a recurring theme. A host of
Read more >>FierceBiotech's most popular stories of 2008
With 2008 behind us, we'd like to take a look back at the stories and special reports our readers found most interesting over the past year. Unlike the 2007 list, which was dominated by Pfizer news,
Read more >>Emerging Drug Developer: Synta Pharmaceuticals
Synta rings in New Year with a new deal The folks at Synta Pharmaceuticals know how to end a year with a bang. While most people were preparing for the Christmas and New Year's holiday bash, Synta
Read more >>Emerging Drug Developer: MAP Pharmaceuticals
MAP Pharma plots a course toward commercialization As the CEO of a public company, there are things Tim Nelson can't talk about, such as just about everything that MAP Pharmaceuticals hasn't
Read more >>Emerging Drug Developer: Ascent Therapeutics
A fledgling biotech launches a new development platform For a newly-sprouted biotech company, Ascent Therapeutics has some deep scientific roots. The technology dates back to the late ‘90s,
Read more >>Emerging Drug Developer: Catalyst Biosciences
Catalyst Biosciences maps out its (near) future Biotech companies have always touted each new round of investment capital as a tangible validation of their development work. And with the capital
Read more >>November FDA news in review
Welcome to the November installment of "FDA News in Review," where each month we look at the agency's latest decision, approvals, warnings and recalls. With a new president on his way to the office,
Read more >>Emerging Drug Developer: Arete Therapeutics
Arete Therapeutics adopts a thrifty approach to drug development With its lead program safely through Phase I testing and a lineup of investors satisfied with the discovery path Arete Therapeutics
Read more >>Emerging Drug Developer: Radius Health
Radius Health maps out its next two years About eight months ago, Radius Health CEO C. Richard Lyttle, PhD, took a hard look at the company's budget as well as the increasingly shaky state of affairs
Read more >>Top 5 layoffs of 2008
Welcome to our second annual report on the top five layoffs of the year. Companies like Pfizer, AstraZeneca and Bayer posted the biggest numbers in 2007. In 2008, patent expirations, drug safety
Read more >>

